MACROGENICS INC.
About MACROGENICS INC.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer and other diseases. Founded in 2000 and headquartered in Rockville, MD, the company is publicly traded on NASDAQ under the ticker MGNX with 293 employees. It has raised a total of $126M across 13 rounds, including multiple post-IPO equity rounds, and counts 31 institutional investors.
- 🔗 MacroGenics - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- 🔗 MacroGenics, Inc. Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 MacroGenics Inc Stock Price Today | NASDAQ: MGNX Live - Investing.com
- 🔗 MacroGenics, Inc. Common Stock (MGNX) Stock Price, Quote, News & History | Nasdaq
- 🔗 MacroGenics Inc News Today (MGNX) - Investing.com
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Publicly traded on NASDAQ (MGNX) with market cap around $237M.
- Clinical-stage developer of antibody-based cancer therapeutics.
- Completed multiple post-IPO equity rounds with institutional participation.
- Headquartered in Rockville, MD with 293 employees.
Ask StreetZero about MACROGENICS INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account